Zacks Research Has Negative Outlook for EW Q2 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Zacks Research decreased their Q2 2025 earnings per share estimates for Edwards Lifesciences in a report released on Tuesday, March 4th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $0.60 per share for the quarter, down from their prior forecast of $0.62. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q3 2025 earnings at $0.60 EPS, Q4 2025 earnings at $0.62 EPS, Q1 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.69 EPS and FY2027 earnings at $3.07 EPS.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%.

A number of other analysts have also recently issued reports on the company. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. Evercore ISI lowered their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Truist Financial reiterated a “hold” rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Citigroup increased their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Trading Down 0.0 %

Shares of EW opened at $71.38 on Wednesday. The stock’s 50-day moving average price is $72.50 and its 200 day moving average price is $70.33. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12-month low of $58.93 and a 12-month high of $96.12. The firm has a market capitalization of $42.10 billion, a price-to-earnings ratio of 10.24, a P/E/G ratio of 4.82 and a beta of 1.10.

Insider Buying and Selling at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,739 shares of company stock worth $2,799,104. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently modified their holdings of EW. Prosperity Consulting Group LLC boosted its stake in Edwards Lifesciences by 3.6% during the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company’s stock worth $289,000 after acquiring an additional 134 shares during the last quarter. Abacus Planning Group Inc. boosted its position in shares of Edwards Lifesciences by 0.3% during the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock worth $2,977,000 after purchasing an additional 140 shares in the last quarter. Bowman & Co S.C. grew its holdings in shares of Edwards Lifesciences by 1.2% in the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after buying an additional 148 shares during the period. Moors & Cabot Inc. increased its position in shares of Edwards Lifesciences by 0.3% in the 4th quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock valued at $4,041,000 after buying an additional 152 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its position in shares of Edwards Lifesciences by 3.1% in the 4th quarter. Quadrant Capital Group LLC now owns 5,180 shares of the medical research company’s stock valued at $383,000 after buying an additional 156 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.